Dalvabancin - Second-Generation Glycopeptide for Serious Gram-Positive Infections
Key Data:
Drug (brand / generic)
Dalbavancin
Company / licensee
Pfizer
Therapy class
Glycopeptide
Product description
Antibiotic
Current indication
Treatment of complicated skin and soft tissue infections due to gram-positive pathogens
Market sector
Antiifectives
Development status
Approved US
